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With the development of new drugs that directly affect CFTR protein function, clinical trials are being designed or initiated for a growing
number of patients with cystic fibrosis. The currently available and accepted clinical endpoints, FEV1 and BMI, have limitations.
The aim of this report is to draw attention to the need and the ample possibilities for the development and validation of relevant gastrointestinal
clinical endpoints for scientific evaluation of CFTR modulation treatment, particularly in young children and infants.
The gastrointestinal tract offers very good opportunities to measure CFTR protein function and systematically evaluate CF related clinical
outcomes based on the principal clinical gastrointestinal manifestations of CF: intestinal pH, intestinal transit time, intestinal bile salt
malabsorption, intestinal inflammation, exocrine pancreatic function and intestinal fat malabsorption.
We present a descriptive analysis of a variety of gastrointestinal outcome measures for clinical relevance, reliability, validity, responsiveness to
interventions, feasibility in particular in young children and the availability of reference values.
© 2015 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Outcome measures; End points; Gastrointestinal; Clinical trials; Intestinal pH; Intestinal transit time; Bile acid metabolism; Intestinal
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In recent years great progress has been achieved in
therapeutic Cystic Fibrosis Transmembrane Corrector (CFTR)
protein modulation. Current CFTR modulation treatment is
based on the use of small molecules, that either improve gating
of ions (“CFTR potentiators”) or restore folding (“CFTR
correctors”) of the CFTR protein to improve its function.
Clinical trials testing CFTR modulators have proven their
success by showing significant clinical improvement, including
sustained improvement in lung function as measured by forced
expiratory volume in 1 s (FEV1), and an increase in body mass
index (BMI) [1,2].
To date the major accepted and established clinical outcome
measures for cystic fibrosis (CF) are FEV1, body weight and
body mass index (BMI). However, unlike previous symptom-
atic treatment approaches for cystic fibrosis, therapeutic CFTR
modulation offers the prospect of early intervention and
possible preemptive treatment. As a consequence, clinical trials
to prove efficacy will be performed in increasingly younger
cystic fibrosis patients [3]. Young children and infants with
cystic fibrosis, in particular those diagnosed via neonatal
screening, may have well preserved lung function and normal
growth. Therefore, development and validation of clinical
outcome measures applicable in this young age group are
imperative.
The gastrointestinal tract offers opportunities to measure
CFTR protein function and systematically evaluate CF related
clinical outcomes for clinical trials. Clinical signs of CFTR
dysfunction in the gastrointestinal tract often occur earlier in
disease development than in the respiratory tract. Meconium
ileus is almost pathognomonic for CF. Meconium ileus will
usually be symptomatic before neonatal screening results are
available. Exocrine pancreatic insufficiency can present at birth
or develop in weeks to months during the first year of life [4].
Additionally the same pathophysiological triad of obstruction,
infection, and inflammation that causes disease in the airways
also causes disease in the intestine [5].
In this position paper we systematically discuss gastrointes-
tinal outcome measurements for cystic fibrosis that are
available to date. We describe clinically measurable outcome
parameters and methods to directly measure CFTR protein
function in gastrointestinal tissues. The aim of the report is to
draw attention to the need and the ample opportunities for the
development and validation of relevant clinical endpoints forscientific evaluation of CFTR modulation treatment, particu-
larly in young children and infants.2. Methods
After an expert group assessment we systematically discuss
potential high-impact gastrointestinal outcome measurements
based on a retrospective literature analysis. We structured our
search for potential GI outcomemeasures on the principal clinical
gastrointestinal manifestations in CF: intestinal pH, intestinal
transit time, intestinal bile salt malabsorption, intestinal inflam-
mation, exocrine pancreatic function and intestinal fat malab-
sorption. We present a descriptive analysis of gastrointestinal
outcome measures for clinical or disease relevance, reliability,
validity, responsiveness to interventions, feasibility in particular
in young children and the availability of reference values. The
results are summarized in the Table 1.3. Results
3.1. Measurements of clinical gastrointestinal manifestations of
cystic fibrosis
3.1.1. Intestinal pH profile
Physiologically, gastric acid is buffered by secretion of
bicarbonate by the pancreas and by the enterocytes of the
proximal small intestine. CFTR is essential for adequate
pancreatic and duodenal bicarbonate secretion. In patients
with CF, the pancreatic and duodenal bicarbonate secretion is
insufficient to neutralize the gastric acid load [6,7]. Hence, the
duodenal pH is (on average) 1–2 units lower in CF patients
compared with healthy controls. Accordingly, CF patients have
significantly longer postprandial periods in which the duodenal
pH is below 4 [8]. In the proximal intestine, acidification may
interfere with absorption both by inhibiting pancreatic enzyme
activity [9] and by causing intraluminal precipitation of bile
acids with impaired mixed micelle formation [10]. More
distally in the small intestine, the pH values of jejunal and
ileal contents from CF patients vary from lower to similar pH
values compared with healthy controls. Bicarbonate secretion is
tightly tied to fluid secretion [11] and in the CF mouse intestine
is essential to allow mucins to unfold and become fluid [12,13].
Thus, the excess acidity in the intestine may contribute to
obstruction.
Table 1
Schematic representation for the availability of the epidemiological qualities of gastrointestinal outcome measures for cystic fibrosis.












pH pill Intestinal pH + ? + + + − +
Scintigraphy intestinal motility + + + ? ? − +
Wireless motility
capsule
Intestinal motility + + + +/− − − +
Plasma C4 Fecal bile salt loss ? ? + ? ? + +/−
Plasma FGF19 Fecal bile salt loss ? ? + ? ? + +/−
Fecal calprotectin Intestinal inflammation ? ? + ? ? + +
GI endoscopy Intestinal inflammation + ? + ? − +/− +
Capsule endoscopy Intestinal inflammation + ? +/− +/− − − +/−
Fecal elastase-1 Exocrine pancreatic function + + + + − + +
CFA Steatorrhoea +/− + +/− + + +/− +
Malabsorption blood test Steatorrhoea +/− + +/− +/− + ? +









+ ? + + ? + +
Intestinal organoid volume + ? ? ? + + ?
+ evidence available.
− no evidence available.
? no information available.
C4: plasma 4-cholesten-3-one.
FGF19: Fibroblast growth factor 19.
CFA: coefficient of fat absorption.
PERT: pancreatic enzyme replacement therapy.
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Gelfond et al. recently showed in CF patients in vivo a deficient
buffer capacity for neutralization of the gastric acid in the proximal
small bowel [14]. In another study using a before-and-after design,
adult patients with the G551D CFTR mutation had abnormal
buffering capacity at baseline but had near normalization of
intestinal pH after taking the CFTR potentiator Ivacaftor [15]. The
latter study indicates the potential role of this clinical tool in
clinical trials. Due to the size of the device, the pH capsule has
limitations for use in children and infants. The correlation between
improved buffering and fat absorption or body weight improve-
ment is not yet available.
3.1.2. Intestinal transit time measurements
Different studies have revealed a prolonged intestinal transit
time in adult and pediatric cystic fibrosis patients with exocrine
pancreatic insufficiency compared to healthy controls [16–18].
The prolonged intestinal transit time is not corrected by
pancreatic enzyme replacement therapy. Possible factors that
may be involved in the prolonged bowel transit time in patients
with CF include the “ileal brake” seen with fat malabsorption,
small bowel bacterial overgrowth, distal intestinal obstruction
syndrome (DIOS), dysmotility disorders (constipation) and a
history of intestinal surgery [17]. In older studies the oro-cecal
transit time (OCTT) using lactulose/hydrogen breath test has
been used to determine small intestinal transit [8]. It revealed
that most cystic fibrosis patients have a measurable prolonged
OCTT of at least +50% in the fasted state [19,20]. While breath
testing is easy to perform, there are limitations that complicateinterpretation and can affect the sensitivity and specificity of
this approach [21].
3.1.2.1. Intestinal transit time scintigraphy. When using
scintigraphy to measure intestinal transit time, subjects ingest
an orally administered radioactive tracer and then are monitored
for the distribution of the tracer within the stomach and small
intestine [22]. Nuclear scanning images are obtained at regular
intervals. The percentage arrival of total small bowel activity at
the terminal ileum and cecum/ascending colon at 6 h can be
used as an index of small intestinal transit time. Intestinal transit
time scintigraphy is considered to be less variable compared
with indirect methods like breath tests. However, the need for
frequent repeated scans makes the method time-intensive.
There is a significant intra-subject biological variability (~20%)
for small bowel transit times [23]. As a consequence the test is
only discriminative in the extreme ranges. Scintigraphy has been
used in clinical trials for intestinal dysmotility and IBS [24,25].
The need for use of a radioactive tracer makes the method less
suitable for routine use in clinical trials or for use in the pediatric
age group.
3.1.2.2. Intestinal transit time wireless motility capsule. A
new option to determine intestinal transit time is the wireless
motility capsule (WMC) System. The WMC can be swallowed
by the subject. Subsequently the transit time through the small
intestine can be determined based on the pH landmarks of
stomach, intestine and colon. The WMC method correlates well
with the scintigraphy method [26]. The WMC does not impose
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ambulatory setting. For determining small intestinal transit time
with the WMC method a sensitivity of 0.42 and a specificity of
0.95 has been reported in patients with constipation when
compared to radiopaque marker studies [27]. The intestinal
transit time wireless capsule has been used to determine the
small bowel transit time in CF patients [28]. It revealed
significant and reproducible delay in the small intestinal transit
of CF patients compared to normal controls. The use of WMC
is limited in young children and infants due to its size
(26 mm × 13 mm) and lack of regulatory approval for use in
children. However, small bowel video capsule endoscopy
devices of similar size (26 mm × 11 mm) have been approved
for use in children down to age 2 years (see below).
3.1.3. Intestinal bile salt malabsorption
A deregulated bile salt homeostasis including increased fecal
bile salt excretion is an intrinsic and consistent phenotype of
cystic fibrosis and presumably directly related to decreased
CFTR protein function. The increased fecal bile salt excretion
is independent from CF related intestinal fat malabsorption or
exocrine pancreatic insufficiency [29]. The measurement of the
total bile salt content in feces over a given period of time is
considered the gold-standard for diagnosing intestinal bile salt
loss. Stool should be collected for at least 48 h or longer to
overcome variation in excretion [30].
Intestinal bile salt malabsorption can also be diagnosed with
the use of radioactive 75Se-labeled homocholic acid-taurine
(75SeHCAT) [31]. Using the SeHCAT method O'Brien et al.
have reported a three-fold higher fecal bile malabsorption in CF
patients compared to healthy controls that was not related to
fecal fat excretion [32]. Although proven to provide significant
and relevant information for the diagnosis of intestinal bile salt
loss, SeHCAT scan is not suitable for wide scale use in clinical
trials because of the need for the use radioactive tracers. New
relevant plasma markers for bile salt synthesis and intestinal
bile salt absorption have recently become available and are
discussed below.
3.1.3.1. Plasma 4-cholesten-3-one (C4). Plasma 4-cholesten-3-
one (C4) is an intermediate product of the bile salt biosynthesis
and a marker of CYP7A1 enzyme activity [33]. CYP7A1 is the
rate-limiting enzyme in the bile salt synthesis in the liver. Thus,
C4 can be used as a marker for hepatic bile salt synthesis. In
patients with increased intestinal bile salt loss, the plasma C4
levels are increased compared to normal controls as a marker of
the compensatory increase in hepatic bile salt synthesis. Thus, C4
can function as a surrogate marker for intestinal bile salt loss.
Perturbations in C4 levels have been reported in several
clinical studies concerning irritable bowel syndrome, inflam-
matory bowel disease and cholestatic liver diseases, however
to date not in cystic fibrosis [34,35]. In patients with bile acid
malabsorption (BAM), either after ileocecal resection surgery
(BAM type 1) or with the idiopathic form of intestinal bile salt
malabsorption (BAM type 2), plasma 4-cholesten-3-one had a
sensitivity/specificity of respectively 90%/77% and 97%/74%,
respectively, to diagnose the intestinal bile salt malabsorption[36]. C4 measurement can be performed in young children and
infants [37]. C4 has been proven to respond to interventional
treatments in patients with an increased fecal bile salt loss
[33,38].
3.1.3.2. Plasma fibroblast growth factor 19 (FGF19). FGF
19 is an intestine-derived signaling protein that functions as an
enterohepatic hormone, regulating hepatic bile acid synthesis
and carbohydrate metabolism. Plasma FGF19 concentration is
a marker of intestinal bile salt re-absorption. In patients with
increased intestinal bile salt loss the FGF19 plasma levels are
decreased as a sign of the disrupted enterohepatic circulation
[39]. In patients with bile salt diarrhea it was reported that
FGF19 was positively related to SeHCAT retention. In non-CF
patients with severe fecal bile salt loss, FGF19 had a sensitivity/
specificity of respectively 67%/77% to diagnose intestinal bile
salt loss [40]. In this same study, Pattni et al. found that FGF19
could reliably predict the clinical response of patients on bile
salt sequestration therapy. Together, these observations indicate
that FGF19 levels can be used for diagnosis in conditions of
intestinal bile loss, in particular also for the detection and quan-
tification of bile salt re-absorption in CF. FGF19measurement can
be performed in young children and infants [41].
3.1.4. Intestinal inflammation
Several studies have shown evidence of intestinal inflam-
mation in cystic fibrosis, particularly in patients with pancreatic
insufficiency. The underlying pathophysiology of intestinal
inflammation is not completely understood. Data from cystic
fibrosis mouse models suggest that the intestinal inflammation
is related to CFTR dysfunction in the intestinal tissues, which
leads to mucus accumulation, disturbed motility, small bowel
bacterial overgrowth and inflammation with altered innate
immune responses. It is to be expected that these different
factors interact with one another [42].
3.1.4.1. Fecal calprotectin. To date several fecal inflammatory
biomarkers are available of which fecal calprotectin is the most
studied and used in the clinical practice [43,44]. Calprotectin is a
very stable protein originating from inflammatory neutrophils. The
value of fecal calprotectin in the diagnosis of intestinal inflam-
mation has been established for inflammatory bowel disease
(IBD). A sensitivity and specificity for fecal calprotectin of 89%
and 81%, respectively, to diagnose IBD, has been reported in
pooled data from adults and children [45]. Additionally, fecal
calprotectin has been successfully used to establish therapeutic
effects of anti-inflammatory agents in clinical IBD trials [46].
Several studies have demonstrated significantly increased fecal
calprotectin levels in cystic fibrosis patients compared to healthy
controls [47]. The fecal calprotectin levels do not seem to be
related to the presence of small intestinal bacterial overgrowth that
is frequently observed in cystic fibrosis patients [48,49]. Clinical
trials using probiotics to treat intestinal inflammation in cystic
fibrosis patients have shown a therapeutic responsiveness of fecal
calprotectin indicating the potential of this marker as a clinical
endpoint [50]. Fecal calprotectin is physiologically increased in
children under the age of 3 years making this marker less suitable
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intestinal inflammation. For example calprotectin is also increased
in pulmonary secretions during lung infections. This should be
taken into consideration in cystic fibrosis where the combination
of pulmonary and intestinal inflammation may coexist.
3.1.4.2. Gastro intestinal endoscopy and intestinal
histology. Video-endoscopy can be performed as an upper
esophageal-gastric-duodenal or ileocolonic endoscopy. In this
manner hallmarks of inflammation can be visualized and scored.
Additionally, tissue for histological assessment can be obtained.
Histological signs of inflammation can by systematically
evaluated using endoscopic biopsy material. Endoscopic evi-
dence for chronic intestinal inflammation in the duodenum of
cystic fibrosis patients has been reported [52,53]. Endoscopy is a
well-established and validated method for identifying intestinal
inflammation and the gold standard to determine therapeutic
effects. However, endoscopic procedures are rather invasive
diagnostic procedures with the necessity for sedation or general
anesthetic making the procedure less applicable for children and
infants.
3.1.4.3. Small bowel capsule endoscopy. A relatively new
option for making the diagnosis of intestinal inflammation is
small bowel capsule endoscopy (SBCE). The primary indica-
tion of SBCE is to examine areas of the small intestine that
cannot be inspected by other types of endoscopy. One study
reported SBCE results in CF patients [49]. The study showed
that most cystic fibrosis patients had varying degrees of diffuse
areas of inflammatory findings in the small bowel including
edema, erythema, mucosal breaks, and frank ulcerations. The
method of SBCE has been well established as a descriptive
diagnostic tool for intestinal inflammation. Sensitivity and
specificity for detecting distal small-bowel Crohn's disease with
SBCE has been reported to be 100% and 91%, respectively [54].
However, systematic quantitative evaluation of SBCE is more
difficult and has not yet been well established. SBCE has been
used as an outcome measure in clinical trials but not yet in
therapeutic trials for cystic fibrosis. SBCE was also approved by
United States Food and Drug Administration (FDA) for use in
children 2 years of age and older [55]. Due to the size of the video
capsule SBCE in young children and infants has to be introduced
via endoscopy, rather than by (attempted) swallowing.
3.1.5. Measures of exocrine pancreatic function
Exocrine pancreatic insufficiency (EPI) develops in most CF
patients with severe CFTR genotypes. EPI is secondary to
CFTR related auto-digestion and fibrosis of pancreas in patients
with severe CFTR mutations. EPI develops mostly in the first
weeks or months of life, however can also develop later in life.
The EPI related maldigestion is treated with pancreatic enzyme
replacement therapy (PERT). To date established EPI in CF is
considered an irreversible disease state. However, it cannot be
excluded that new CFTR modulation therapies may be able to
improve already developed EPI and the intestinal absorption of
nutrients. Support for this possibility can be derived from the
ivacaftor trials showing an improved intestinal pH upon treatment,which, at least partly, may be due to improved pancreatic
bicarbonate secretion. If EPI could be shown to be completely or
partially reversible, this could be interpreted as a measurement of
restoration of pancreatic CFTR function. Therefore, it is
reasonable to monitor the exocrine pancreatic function in clinical
trials with CFTR modulators in particular young children and
infants. The most used and widely available exocrine pancreatic
function test is the measurement of fecal elastase-1 [56]. Other
tests include direct pancreatic function measurement via the
secretin-cholecystokinin (CCK) stimulation test and serum
immunoreactive trypsinogen (IRT) measurement [57,58].
3.1.5.1. Fecal elastase-1. Fecal elastase-1 is one of the
proteolytic pancreatic enzymes. In the intestine elastase-1 is not
subject to degradation. It is pH and temperature stabile and is
excreted via the feces. A small fecal sample can easily be
obtained and stored. Elastase-1 has no cross reactions with
chymotrypsin of animal sources that is present in exogenous
submitted pancreatic enzymes (PERT). For this reason elastase-1
can still be used a marker of exocrine pancreatic function during
PERT use. In the case of exocrine pancreatic insufficiency fecal
elastase-1 is decreased. Reference values of fecal elastase-1 have
been established [59]. The positive predictive value of a fecal
elastase-1 of less than 100 μg/g for detecting pancreatic insuffi-
ciency in patients with cystic fibrosis is very good; a negative test
(N100 μg/g stool) has 99% predictive value for ruling out EPI
[60]. The level of fecal elastase-1 varies with age. Fecal elastase-1
is low in meconium. Normal values are reached within 3 days
after birth and in 2 weeks in premature infants independent of
gestational age. Hereafter fecal elastase-1 values in children are
comparable to adult levels.
3.1.5.2. Direct pancreatic enzyme secrets measurements. The
CCK test is considered the gold standard in the evaluation of
exocrine pancreatic insufficiency. A tube is passed into the
duodenum to enable the collection of secretions for analysis.
Secretin and CCK are cholecystokin given intravenously.
Duodenal aspiration samples are taken at set intervals for
analysis. The CCK test has between reported for use in patients
with CF and is capable of reliably differentiating EPI from PS
patients [61]. However, the procedure is complex, invasive,
expensive and time consuming. Globally, only a few centers
have the experience to perform the sampling and enzyme
analysis. These drawbacks make this method less suitable as an
endpoint measurement method for clinical trials in particular in
young children and infants.
3.1.5.3. Serum immunoreactive trypsinogen. Trypsinogen is
the precursor protein of trypsin that is synthesized and stored in
the pancreas and released into the small intestine. Trypsinogen
is also secreted into the blood by the pancreas. A particular
isoform (cationic), IRT, can then be measured in serum using
radioimmunoassay. IRT can be elevated in conditions like
pancreatitis. IRT is decreased compared to normal controls in
the situation of complete EPI. However in infants and children
with CF who develop EPI over the course of the first years of
life a distinct pattern for the IRT has been observed. In the
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normal IRT values. Over the course of several years the IRT
levels decrease gradually below normal values indicating EPI.
As a result of this fluctuating pattern in the first decade of life,
IRT is not suitable for determining EPI in infants. IRT can,
however reliably, determine EPI in children with CF over
7 year of age [57].
3.1.6. Intestinal fat malabsorption
A prominent feature of the gastrointestinal cystic fibrosis
phenotype is intestinal fat malabsorption ([62]. Intestinal fat
malabsorption in CF is related primarily to two pathological
mechanisms. The first is disrupted lipolysis of dietary triglycer-
ides primarily caused by EPI. A decreased bile salt pool and/or
precipitation of bile salts can impair micelle formation leading to
an impairment of the intestinal, post-lipolytic, absorption of free
fatty acids and monoglycerides.
3.1.6.1. Coefficient of fat absorption. The coefficient of fat
absorption (CFA) is the current clinical standard for measuring
intestinal fat absorption. CFA compares the dietary fat intake to
the fecal fat excretion measured over a period of 72 hours
[63,64]. CFA has historically often been used as an outcome
measure in clinical trials. CFA has been shown to measure
therapeutic effects in particular of PERT medication. The CFA
methods measure the total fat excreted and do not differentiate
between lipolytic or post-lipolytic fat malabsorption. The
advantage of the lack of discrimination is that irrespective of
the pathophysiological mechanism by which CF affects fat
absorption, the clinically relevant result is quantified. In
patients with CF, CFA is largely influenced by the use and
effectiveness of PERT, although some patients may have
moderate to severe steatorrhea as measured by CFA, despite
seemingly adequate doses of PERT [65]. To a lesser extend CFA
may reflect changes the intestinal CFTR protein function. CFA
has several drawbacks in both the execution and interpretation.
Therefore it can be difficult to achieve research-quality CFA
measurements in infants, toddlers and young children [66].
However selected use of carefully-conducted fecal fat balance
studies may help clarify whether the weight gain seen with CFTR
modulation is as a result of improved fat absorption.
3.1.6.2. Stable isotope free fatty acid absorption test. If a
more detailed analysis is warranted to determine whether the fat
malabsorption is mainly due to impaired lipolysis or to impaired
uptake of fatty acids, other tests are available. The free fatty acid
absorption can be quantified using the stable isotope free fatty
acid absorption test. In this test intestinal absorption of the
non-radioactive 13C-labeled dietary free fatty acid is estimated
based on plasma enrichment of the label after oral ingestion.
If required, the stable isotope free fatty acid can be combined
with a stable isotope labeled triglyceride. The stable isotope free
fatty acid absorption test has been used in CF patients and can be
performed in young children and even infants [67,68] In a stable
isotope study in CF patients a strong relation was demonstrated
between free fatty acid absorption and CFA (r = 0.88, P b 0.001)
[67]. In term and preterm neonates the stable isotope free fattyacid absorption highly correlated with the efficacy of fat
absorption (r = 0.82, p = 0.02; and r = 0.91, p = 0.004; respec-
tively) [68]. No reports are available for using the stable isotope
free fatty acid test in the setting of CFTR modulating trials.3.1.6.3. Malabsorption Blood Test. The Malabsorption Blood
Test (MBT) is a new method to assess the degree of intestinal fat
malabsorption. It is based on the principle of comparing the
simultaneous absorption of a free fatty acid (pentadecanoic acid)
and a triglyceride (triheptadecanoic acid) requiring hydrolysis
before intestinal absorption. These marker lipids can be quan-
tifiably measured in the blood after intestinal absorption as a
reflection of intestinal fat absorption. In a pilot study it was
demonstrated that in subjects over 12 years of age, the MBT has
been shown to respond to changes in fat absorption in healthy
subjects using a lipase inhibitor and in subjects with CF while on
or off enzyme therapy [69].
Although potentially an absorption blood test offers a practical
alternative for the CFA it has to be taken into consideration that
plasma measurements of fatty acids levels do not necessary
reflect the total intestinal absorptive capacity of dietary lipids
[70].3.2. Direct CFTR function measurement in the intestine
3.2.1. Intestinal electric current measurements (ICM)
Intestinal electrical current measurement (ICM) is an ex vivo
electrophysiological method in which a freshly obtained rectal
biopsy is evaluated for its electrical responses related to chloride
ion transport. The procedure is performed by mounting a fresh
rectal biopsy in an Ussing chamber and adding a series of
chemicals baths stimulating secretion (secretagogues), according
to reported protocols [71]. It is a method that assesses functional
CFTR activity. There is a clear difference in ICM between normal
(non CF) and abnormal (CF) results. Considerable technical
expertise is required to place the tissue in the Ussing chamber and
add the secretagogues in the correct manner. The potential of ICM
was recently extensively reviewed in several reports [72–74]. ICM
is a safe method that is used as a diagnostic aid for non-classic
cases of CF mainly in infants and young children. ICM changes
have not been reported in relation to CFTR modulation.3.2.2. Intestinal organoid volume measurement (IOVM)
Intestinal organoids are ex-vivo stem cell-derived human
epithelial ‘mini-organs’ from tissues of patients that closely
resemble the organ structure and function of intestinal mucosa.
Intestinal organoids can be derived from rectal biopsy specimens
of patients. Rectal biopsies can be obtained safely in newborns
and infants. Organoids of individual patients can be stored for
later ex-vivo use or testing. Intestinal organoid volume measure-
ments have been developed and have been shown to indirectly
represent CFTR protein function [75]. Furthermore quantitative
changes in organoid volume have been related to changes in
therapeutic modulation of CFTR function [76].
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Clinical trials with CFTR modulators are currently being
designed and implemented for increasing numbers of patients.
The CFTR modulator ivacaftor already has proven to improve
lung function and body weight in the older children and adults
with the G551D CFTR mutation. However, additional treatment
options for other CFTR mutations types and treatments early in
disease development are currently pursued. In the future, even
preemptive or preventive treatment could be considered.
The gastrointestinal tract offers several unique opportunities to
study CFTR protein function and CFTR related clinical outcome
measures. Importantly many of the gastrointestinal manifesta-
tions of cystic fibrosis are already present at birth or in childhood,
making them potentially suitable for studying treatment effects in
young children and infants. However, not all GI outcome
measures are feasible to perform in small children.
Less emphasis has been given to the development of gas-
trointestinal outcome measures for therapeutic trials in cystic
fibrosis than for pulmonary outcome measures. This was partially
due to the presumed irreversible character of CF gastrointestinal
manifestations, for example exocrine pancreatic insufficiency.
Different from pulmonary disease, some GI manifestations of CF
do not present with clinically recognizable and relevant disease.
For example, diminished GI bicarbonate secretions or fecal bile
salt loss, clear entities of the CF phenotype, do not directly
correlate to a distinct clinical pathology. The current studies with
CFTR modulators offer new and promising opportunities to
implement GI outcomemeasures for cystic fibrosis, and the use of
GI outcomemeasures can provide evidence of the systemic action
of these medications.
Although promising, many of the gastrointestinal outcome
measures suggested and discussed in this paper still have to be
further developed into valid clinical endpoint for use in clinical
trials. To date some gastro-intestinal outcome measures are already
evaluated in post marketing evaluations of CFTR modulators. The
goal to develop new outcome measures should be a joint ambition
of all institutional partners involved in drug development for cystic
fibrosis. Academics and CF clinical researchers strive to provide
the opportunities and theoretical background for potential new
outcome measures. Pharmaceutical companies understand the
shared obligation to support outcome measure development.
Medicine regulatory bodies, like the U.S. Food and Drug
Administration and European Medicines Agency, support and
enforce outcome measure development in their advice and
legislation. Additionally, CF patient interest groups prioritize
and support endpoint development as an important goal for
cystic fibrosis. Together, all stakeholders can help expand our
understanding of the underlying pathophysiology of CF and
advance our ability to bring new treatments to the benefit of
individuals with CF.Conflict of interest
The authors report no conflicts of interest related to the subject
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